Efficacy and safety of intravenous and oral diltiazem for Wolff-Parkinson-White syndrome
- 1 February 1987
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 59 (4), 301-306
- https://doi.org/10.1016/0002-9149(87)90803-4
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Termination of paroxysmal supraventricular tachycardia with a single oral dose of diltiazem and propranolol.Circulation, 1985
- Usefulness of intravenous diltiazem in predicting subsequent electrophysiologic and clinical responses to oral diltiazemThe American Journal of Cardiology, 1984
- Effects of oral diltiazem in paroxysmal supraventricular tachycardiaThe American Journal of Cardiology, 1983
- Effects of oral verapamil in patients with atrioventricular reentrant tachycardia incorporating an accessory pathway.Circulation, 1983
- Beneficial effect of intravenous diltiazem in the acute management of paroxysmal supraventricular tachyarrhythmias.Circulation, 1983
- Electrophysiologic effects of diltiazem hydrochloride on supraventricular tachycardiaThe American Journal of Cardiology, 1982
- Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil.Circulation, 1982
- Effect of lidocaine on atrioventricular response via the accessory pathway in patients with Wolff-Parkinson-White syndrome.Circulation, 1981
- Electrophysiologic Effects of Diltiazem, a Calcium Antagonist, in Patients With Impaired Sinus or Atrioventricular Node FunctionAngiology, 1980
- Verapamil in the treatment of paroxysmal supraventricular tachycardiaPostgraduate Medical Journal, 1974